Oslo, Norway, 23 August 2016: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a sales revenue growth of 18 % to NOK 34.2 million in the second quarter of 2016 (Q2 2015: NOK 28.9 million) for the Hexvix/Cysview commercial franchise and a corresponding EBITDA of NOK 5.9 million."Photocure continued to progress with underlying revenue growth during the second quarter. It is especially encouraging to see the positive momentum of Cysview in the US, both in regard to continued volume growth and expansion in the base of installed blue light enabled cystoscopes, as well as the recommendation of Cysview in the US bladder cancer guidelines. This event is an important foundation for future investments and growth of our flagship brand", says Kjetil Hestdal, president and CEO.
08:30 - 09:05 Q2 presentation by Kjetil Hestdal, President and CEO, and Erik Dahl, CFO. The presentation will be held in Norwegian.
09:05 - 09:15 Break
09:15 - 09:45 Dr. Sia Daneshmand, MD, Associate Professor of Urology (Clinical Scholar); Director of Urologic Oncology, Director of Research and FellowshipDirector, USC Institute of Urology at University of Southern California, Los Angeles, USA. The presentation will be held in English.
09:45 - 10:00 Ambaw Bellete, President, Photocure Inc. and Head, US Commercial Operations. The presentation will be held in English.
Photocure will additionally host an audio webcast and conference call ( http://webtv.hegnar.no/presentation.php?webcastId=36207441 ) the same day in English at 17:00 CET / 16:00 GMT / 12:00 EST.
Please join the event conference 5-10 minutes prior to the start time using the number and confirmation code below:
Confirmation code: 6357841
It is possible to listen to a replay of the conference call on the following numbers:
Confirmation code: 6357841
For further information, please contact:
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535
CFO Erik Dahl
Tel: +47 450 55 000
Trout International LLC
Tel: +44 20 3780 4972
Notes to editors
About Photocure ASA
Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology(TM) platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com
Last updated on: 24/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.